Loading...
•
Jun 30, 2025
•/
Nyxoah SA Q2 2025 Earnings Report
Nyxoah SA reported Q2 2025 results highlighted by FDA approval of its Genio system and strong revenue growth.
Key Takeaways
Nyxoah posted €1.34 million in revenue for Q2 2025, a 74% increase YoY, following the FDA approval of its Genio system and the beginning of its U.S. commercial launch. The company reported a net loss of €20.6 million, driven by increased commercialization and R&D investments.
Revenue rose 74% YoY to €1.34 million driven by early Genio system sales.
Gross margin remained strong at 63.4%.
Net loss widened to €20.6 million due to ramp-up in U.S. commercial launch activities.
Cash and financial assets declined to €43 million from €63 million in Q1.
Revenue by Segment
Forward Guidance
Nyxoah expects transformational growth ahead with the U.S. commercial rollout of the Genio system now underway.
Positive Outlook
- First and only bilateral hypoglossal neurostimulation system approved in the U.S.
- Strong DREAM trial data supports efficacy across sleep positions.
- Commercial infrastructure in place for U.S. launch.
- CE Mark expansion allows access to CCC patients in Europe.
- Access to €27.5 million in undrawn term debt for strategic flexibility.
Challenges Ahead
- Operating losses expected to continue amid commercial scale-up.
- Cash burn intensified with €20M+ net loss in Q2.
- R&D and SG&A expenses significantly increased YoY.
- Currency and macroeconomic pressures could impact European operations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...